As the in-vitro data suggested that RXRA ligands improved imatinib sensitivity and inhibited BCR-ABL downstream signaling in CML cell lines and primary CML cells, we investigated the in-vivo efficacy of acitretin combined with imatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.